Stephanos J. Hadziyannis

Stephanos J. Hadziyannis's AcademicInfluence.com Rankings

Philosophy

#7756

World Rank

#11007

Historical Rank

Logic

#4792

World Rank

#6121

Historical Rank

philosophy Degrees

Stephanos J. Hadziyannis

Biology

#10472

World Rank

#13805

Historical Rank

Virology

#246

World Rank

#253

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Stephanos J. Hadziyannis Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stephanos J. Hadziyannis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. (2004) (2954)
EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009) (1471)
Molecular Cloning and Disease Association of Hepatitis G Virus: A Transfusion-Transmissible Agent (1996) (1396)
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. (2004) (1118)
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. (2003) (1015)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. (2006) (879)
Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. (1981) (693)
Hepatitis B e antigen–negative chronic hepatitis B (2001) (593)
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α‐2a (40 kd)/ribavirin therapy (2006) (543)
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. (2005) (462)
Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B (2009) (430)
Occurrence of hepatocellular carcinoma and decompensation in western european patients with cirrhosis type B (1995) (405)
Analysis of Liver Disease, Nuclear HBcAg, Viral Replication, and Hepatitis B Virus DNA in Liver and Serum of HBcAg Vs. Anti‐HBe Positive Carriers of Hepatitis B Virus (2007) (385)
Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B (2000) (369)
Adding‐on versus switching‐to adefovir therapy in lamivudine‐resistant HBeAg‐negative chronic hepatitis B (2007) (340)
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. (2009) (317)
Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. (2012) (286)
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B (2006) (280)
Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C (2004) (280)
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study (1994) (274)
Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. (2006) (271)
The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B (2001) (251)
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. (2005) (245)
Adefovir dipivoxil for wait‐listed and post–liver transplantation patients with lamivudine‐resistant hepatitis B: Final long‐term results (2007) (237)
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil (2003) (224)
Outcome of hepatitis B e antigen–negative chronic hepatitis B on long‐term nucleos(t)ide analog therapy starting with lamivudine (2005) (223)
Course of virologic breakthroughs under long‐term lamivudine in HBeAg‐negative precore mutant HBV liver disease (2002) (218)
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. (2007) (216)
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. (2011) (206)
Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B (2001) (199)
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis (1998) (193)
Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy (1997) (182)
Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients (2006) (178)
Efficacy and safety of peginterferon alfa‐2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis (2010) (163)
Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis (1991) (161)
Prediction of Treatment-Related HBsAg Loss in HBeAg-Negative Chronic Hepatitis B: A Clue from Serum HBsAg Levels (2007) (159)
Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. (2004) (159)
Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. (2011) (155)
Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose (2002) (153)
The spectrum of extrahepatic manifestations in hepatitis C virus infection (1997) (152)
The Natural History of Chronic HBV Infection and Geographical Differences (2010) (146)
Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. (1990) (139)
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients (2012) (133)
Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus‐related cirrhosis: a meta‐analysis (2001) (128)
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. (2001) (124)
Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. (2001) (122)
Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. (1984) (118)
Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen–negative chronic hepatitis B virus infection (2003) (116)
Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial (1995) (114)
Diagnosis and management of pre‐core mutant chronic hepatitis B (2001) (112)
Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis (2003) (111)
Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). (1994) (109)
Systematic review: cessation of long‐term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B (2015) (106)
Management of hepatitis C virus genotype 4: recommendations of an international expert panel. (2011) (104)
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature (2000) (92)
Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. (1998) (91)
REVIEW: Hepatitis delta (1997) (91)
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. (2013) (89)
Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action (1998) (86)
Treatment of HBeAg-negative chronic hepatitis B. (2003) (78)
Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. (2003) (77)
Liver disease activity and hepatitis B virus replication in chronic delta antigen‐positive hepatitis B virus carriers (1985) (77)
Recombinant interferon‐α therapy for acute hepatitis B: a randomized, double‐blind, placebo‐controlled trial (1997) (76)
Fulminant hepatitis associated with hepatitis B virus e antigen–negative infection: Importance of host factors (1995) (75)
A case‐control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma (1995) (75)
Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. (2004) (75)
Old and emerging therapies in chronic hepatitis C: an update (2007) (73)
Early Predictors of Anemia in Patients With Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a (40KD) Plus Ribavirin (2008) (70)
Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. (1988) (70)
Hepatitis B e antigen negative chronic active hepatitis: hepatitis B virus core mutations occur predominantly in known antigenic determinants (1995) (68)
P.102 Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy (2006) (68)
Hepatitis B virus core protein mutations are concentrated in B cell epitopes in progressive disease and in T helper cell epitopes during clinical remission. (1997) (67)
Other clinical studyOccurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B (1995) (67)
Immune thrombocytopenia and α-interferon therapy (1996) (66)
Current management of chronic hepatitis B (2004) (65)
In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. (2002) (64)
Skin diseases associated with hepatitis C virus infection (1998) (64)
Retreatment of chronic hepatitis B e antigen–positive patients with recombinant interferon alfa‐2a (1999) (62)
Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin (2007) (58)
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. (2010) (58)
Neurovisual impairment: A frequent complication of alpha‐interferon treatment in chronic viral hepatitis (1998) (56)
Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis (2008) (52)
Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial (2002) (52)
Hepatitis C virus 1b is the dominant genotype in HCV‐related carcinogenesis: A case‐control study (1996) (50)
Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece (2005) (50)
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon α‐2a plus ribavirin (2007) (49)
Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. (2015) (49)
Assessment of Depression in Patients with Chronic Viral Hepatitis: Effect of Interferon Treatment (2003) (47)
Immunopathogenesis of hepatitis B e antigen negative chronic hepatitis B infection. (2001) (46)
Peginterferon alfa‐2a (40kDa) and ribavirin: comparable rates of sustained virological response in sub‐sets of older and younger HCV genotype 1 patients (2009) (45)
[8] SHOULD TREATMENT WITH PEGINTERFERON PLUS RIBAVIRIN BE INTENSIFIED IN PATIENTS WITH HCV GENOTYPE 2/3 WITHOUT A RAPID VIROLOGICAL RESPONSE? (2007) (45)
Serum HBV-DNA levels in inactive hepatitis B virus carriers. (2002) (45)
Hepatitis G virus infection: clinical characteristics and response to interferon (1997) (43)
Optic tract neuropathy complicating low-dose interferon treatment. (1994) (43)
57 Long-term incidence of adefovir dipivoxil (ADV) resistance in chronic hepatitis B (CHB) patients after 144 weeks of therapy (2004) (41)
Differences in epidemiology, liver disease and treatment response among HCV genotypes. (2004) (40)
Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species. (1997) (39)
Hepatic expression of the proliferative marker Ki‐67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma (2005) (39)
46 Three year study of adefovir dipivoxil (ADV) demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES) (2004) (39)
Immune thrombocytopenia and alpha-interferon therapy. (1996) (39)
Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa‐2b for 6 or 12 months: A 4‐year follow‐up of 211 patients (1997) (39)
Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research. (2000) (38)
Hepatitis C virus infection in Greece and its role in chronic liver disease and hepatocellular carcinoma. (1993) (38)
Endemic hepatitis delta virus infection in a Greek community. (1987) (38)
Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma. (1997) (38)
High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma. (2011) (37)
Review article: current management of chronic hepatitis B. (2004) (36)
Assessment of depression in patients with chronic hepatitis: effect of interferon treatment. (2002) (36)
Fulminant hepatic failure as a presenting paraneoplastic manifestation of Hodgkin's disease. (1999) (36)
Nonhepatic manifestations and combined diseases in HCV infection (1996) (35)
Fulminant hepatitis after flutamide treatment. (1994) (35)
Diabetes mellitus and chronic hepatitis C virus infection (1999) (34)
Chronic hepatitis B: a critical appraisal of current approaches to therapy. (2006) (34)
Peginterferon-α2a (40 kDa) for chronic hepatitis C (2003) (32)
Effect of helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. (2004) (32)
Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience. (2002) (32)
Expression of pre-S gene-encoded proteins in liver and serum during chronic hepatitis B virus infection in comparison to other markers of active virus replication. (1987) (32)
Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. (2002) (31)
Does delta infection play a part in the pathogenesis of hepatitis B virus related hepatocellular carcinoma? (1984) (31)
Use of α-interferon in the treatment of chronic delta hepatitis (1991) (30)
Milestones and perspectives in viral hepatitis B (2011) (30)
Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study. (1999) (30)
Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients (2007) (29)
Thursday, 24 AprilParallel Session 1: HEPATITIS C THERAPY7 RAPID VIROLOGICAL RESPONSE IS A MORE IMPORTANT PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE (SVR) THAN GENOTYPE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION (2008) (29)
80 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026) (2006) (28)
Could HGV infection be implicated in lymphomagenesis? (1997) (27)
Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B (2007) (27)
Overlapping syndrome of autoimmune hepatitis and primary sclerosing cholangitis associated with pyoderma gangrenosum and ulcerative colitis. (1999) (26)
A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen‐negative chronic hepatitis B (2006) (25)
18 OUTCOME OF HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHB) 5 YEARS AFTER DISCONTINUATION OF LONG TERM ADEFOVIR DIPIVOXIL (ADV) TREATMENT (2009) (25)
Serum β2 microglobulin in malignant lymphoproliferative disorders (1985) (25)
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection (2004) (25)
New developments in the treatment of chronic hepatitis B (2006) (24)
Whole genome analysis of hepatitis B virus from four cases of fulminant hepatitis: genetic variability and its potential role in disease pathogenicity (1996) (24)
Gliclazide-induced acute hepatitis. (2000) (23)
[53] VIROLOGICAL AND BIOCHEMICAL RESPONSE IN PATIENTS WITH HBeAg-NEGATIVE CHB TREATED WITH PEGINTERFERON a-2a (40 kD) ± LAMIVUDINE: 3-YEAR FOLLOW-UP RESULTS (2007) (23)
The natural course of chronic hepatitis B virus infection and its management. (2013) (23)
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin. (2012) (22)
Changing relative roles of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in Greece. Epidemiological and clinical observations (2003) (22)
The role of entecavir in the treatment of chronic hepatitis B (2007) (22)
Use of alpha-interferon in the treatment of chronic delta hepatitis. (1991) (22)
483 Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in HBeAg-negative patients (2006) (22)
Successful management of postoperative chylous ascites with a peritoneojugular shunt. (1995) (22)
Hashimoto Encephalopathy with Pegylated Interferon Alfa-2b and Ribavirin (2005) (21)
Autoimmune hepatitis associated with the antiphospholipid syndrome. (2001) (21)
Unrevealing the natural course of the so-called “inactive HBsAg or HBV carrier state” (2007) (21)
Treatment of special populations with chronic hepatitis B infection (2011) (20)
GS-98-438 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 week results (2002) (19)
Changing epidemiology and spreading modalities of hepatitis delta virus infection in Greece. (1993) (19)
Fulminant hepatitis and the new G/GBV‐C flavivirus (1998) (19)
Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B (2003) (18)
Serum hepatitis delta virus RNA in patients with delta hepatitis and in liver graft recipients. (1990) (18)
Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility (2014) (18)
Serum beta 2 microglobulin in malignant lymphoproliferative disorders. (1985) (18)
Induction interferon therapy in naïve patients with chronic hepatitis C: increased end‐of‐treatment virological responses but absence of long‐term benefit (2001) (18)
Heat stroke and multi-organ failure with liver involvement in an asylum-seeking refugee. (2006) (17)
The precore sequence of hepatitis B virus is required for nuclear localization of the core protein (1997) (17)
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon α‐2a (40KD) plus ribavirin (2007) (17)
EDITORIAL: Decreasing prevalence of hepatitis D virus infection (1997) (16)
The role of the hepatitis delta virus in acute hepatitis and in chronic liver disease in Greece. (1991) (16)
Cellular immune responses in hepatitis B virus e antigen negative chronic hepatitis B (2008) (15)
Intracellular distribution of hepatitis B virus core protein expressed in vitro depends on the sequence of the isolate and the serologic pattern. (2004) (15)
189 Treatment of chronic hepatitis C with peginterferon ALFA-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response (2003) (15)
Treatment of HBeAg negative chronic hepatitis B with new drugs (adefovir and others). (2003) (14)
Nonalcoholic fatty liver disease: from clinical recognition to treatment (2008) (14)
Decreasing prevalence of hepatitis D virus infection. (1997) (14)
95 Peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy is more effective than lamivudine monotherapy in the treatment of HBEAG-negative chronic hepatitis B: 72-week results from a phase III, partially double-blind study of PEGASYS® alone vs PEGASYS® plus lamivudine vs lamivudine (2004) (14)
Emerging treatments in chronic hepatitis B (2004) (13)
Discontinuation of long-term NA therapy in HBeAg-negative chronic hepatitis B (2014) (13)
Safety of peginterferon alfa‐2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients (2012) (13)
[613] VIROLOGICAL RESPONSE AT 4 AND 12 WEEKS PREDICT HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE IN GENOTYPE 1 PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN (2007) (13)
Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B (2005) (13)
Expression of immunoreactive forms of the hepatitis C NS5A protein in E. coli and their use for diagnostic assays (2002) (13)
Absence of the negative strand of GBV-C/HGV RNA from the liver (1999) (13)
Clinical significance of quantitative anti-HBc IgM assay in acute and chronic HBV infection. (1993) (13)
Post-Infantile Giant Cell Hepatitis Associated with Autoimmune Hepatitis and Polyarteritis Nodosa (2002) (13)
505 The influence of cumulative exposure to combination peginterferon alfa-2A (40 KD) (Pegasys) and ribavirin on sustained virological response (SVR) rates in patients with genotype 1 chronic hepatitis C (2004) (12)
INFECTION WITH THE NOVEL GB-C VIRUS IN MULTIPLY TRANSFUSED PATIENTS AND IN VARIOUS FORMS OF CHRONIC LIVER DISEASES (1995) (12)
Hepatocellular carcinoma and type B hepatitis. (1980) (12)
Erratum: impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: Results of a European concerted action (Journal of Hepatology (1998) 29 (173-83)) (1998) (12)
Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy. (2002) (12)
Prolonged cholestatic jaundice after endoscopic retrograde cholangiography. (1997) (11)
Characterization of secreted and intracellular forms of a truncated hepatitis C virus E2 protein expressed by a recombinant herpes simplex virus. (2003) (11)
Fertility and Sex Ratio of Offspring of Female HBsAg Carriers (1979) (11)
The variety of responses within a community to infection with Australia (hepatitis B) antigen. (1975) (10)
Chronic hepatitis B. (1990) (10)
Update on Hepatitis B Virus Infection: Focus on Treatment (2014) (10)
75 TENOFOVIR DISOPROXIL FUMARATE (TDF) IS HIGHLY ACTIVE FOR TREATMENT OF CHRONIC HEPATITIS B IN SUBJECTS WITH CIRRHOSIS (2008) (10)
Expression of HBsAg and HBcAg in liver tissue: correlation with disease activity. (1992) (9)
522 Combination therapy with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR) (2004) (9)
Precore mutant chronic hepatitis B - approach to management. (2003) (9)
Telbivudine in the treatment of chronic hepatitis B (2008) (9)
Ileoileocecal intussusception in an adult caused by a lipoma of the terminal ileum (2007) (9)
Acute chest syndrome in sickle-cell trait; Two case reports in persons of Mediterranean origin and review of the literature. (2004) (9)
CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Sustained Response of Hepatitis B e Antigen-Negative Patients 3 Years After Treatment with Peginterferon Alfa-2a (2009) (9)
743 The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] sustain responses 2 years post-treatment (2006) (9)
Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B. (1998) (9)
S1001 Clearance of HCV At 5 Year Follow-Up for Peginterferon Alfa-2b ± Ribavirin Is Predicted By Sustained Virologic Response At 24 Weeks Post Treatment (2008) (8)
Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in HBEAG-negative and -positive patients with chronic hepatitis B who have failed prior lamivudine therapy (2003) (8)
Long-term safety of adefovir dipivoxil (ADV) 10 MG once daily for chronic hepatitis B (CHB): An integrated analysis of two phase III studies (2003) (8)
Complex management issues: management of HCV in the atypical patient. (2000) (8)
Ursodeoxycholic-acid for primary biliary cirrhosis: Final results of A12-year prospective, randomised, controlled trial (2000) (8)
Sex-related differences in immunoglobulin M and in total antibody response to hepatitis A virus observed in two epidemics of hepatitis A. (1984) (7)
The effect of low-dose interferon treatment on visual evoked potentials (1997) (7)
Common ABCB1 polymorphisms in Greek patients with chronic hepatitis C infection: A comparison with hyperlipidemic patients and the general population. (2016) (7)
Why and how to treat chronic hepatitis C. (2000) (7)
Deep jaundice in an adolescent (2003) (7)
Treatment of HBeAg-Negative Chronic Hepatitis B with Nucleoside/Nucleotide Analogs (2004) (7)
Combined hepatocellular-cholangiocarcinoma presented with massive pulmonary embolism. (2000) (7)
OMGE--Study on prevalence of hepatitis B surface antigen in different liver diseases. (1979) (6)
Hepatocellular carcinoma after treatment cessation in non‐cirrhotic HBeAg‐negative chronic hepatitis B: A multicentre cohort study (2021) (6)
Core Protein Evolution After Selection of Hepatitis B Precore Mutants and Correlation with Disease Severity (1994) (6)
21 TWO YEARS SAFETY AND EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH HBV-INDUCED CIRRHOSIS (2009) (6)
Concurrent Hepatitis B, Delta and Human Immunodeficiency Virus Infection in Hemophiliacs (1987) (6)
683 ON-TREATMENT HBSAG DECLINE IN HBEAG-NEGATIVE PATIENTS AS A PREDICTOR OF RESPONSE TO PEGINTERFERON ALFA-2A (40KD) THERAPY 3 YEARS POST-TREATMENT: POTENTIAL FOR RESPONSE-GUIDED THERAPY (2008) (6)
Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B? (2014) (6)
1181 A phase III, partially double-blinded study evaluating the efficacy and safety of peginterferon alfa-2A (40KD) (PEGSYS®) alone or in combination with lamivudine vs lamivudine in 546 patients with HBEAG-negative/anti-HBE-positive chronic hepatitis B (2003) (6)
Famciclovir treatment of anti-HBE+ chronic hepatitis B: Results of a randomized, placebo-controlled study (2000) (6)
Lymphoblastoid interferon in controlled trials of chronic hepatitis B virus infection (1988) (6)
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies (2012) (5)
Hepatitis C virus 1b is the dominant genotype in HCV-related carcinogenesis: A case-control study (1997) (5)
CT portography and post-lipiodol CT in the preinterventional work-up of primary and secondary liver tumors. A single center experience. (1999) (5)
241 Long-term (96 weeks) adefovir dipivoxil in HBEAG negative chronic hepatitis results in significant virological, biochemical and histological improvement (2003) (5)
Peginterferon-?2a (40kDa) for chronic hepatitis C (2003) (5)
W1806 Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis (2009) (5)
428 Lamivudine-refractory hepatitis B patients can be safely switched directly to entecavir 1 mg daily therapy (2004) (5)
Recent peginterferon and ribavirin combination trials (2004) (5)
[792] IMPACT OF ADEFOVIR DIPIVOXIL ON LIVER FIBROSIS AND ACTIVITY ASSESSED WITH FIBROTEST-ACTITEST IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION (2007) (5)
Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B (2020) (5)
774 BASELINE AND ON-TREATMENT FACTORS ASSOCIATED WITH HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH AND WITHOUT CIRRHOSIS FOLLOWING TREATMENT WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (2008) (4)
Complement Levels in Relation to Certain Antibodies in Polytransfused Thalassaemic Patients 1 (1976) (4)
Acute rhabdomyolysis following quail consumption. (2001) (4)
Splenic infarct as a late complication of liver transplantation. (1998) (4)
Practical Management of Liver Diseases: Chronic Hepatitis B and D (2008) (4)
Splenomegaly in asymptomatic chronic carriers of hepatitis B and D viruses (1994) (4)
2 Safety and efficacy of adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B undergoing liver transplantation (2006) (4)
Long-term alpha-interferon therapy in anti-HBe positive chronic hepatitis B increases significantly the frequency of sustained response (1994) (4)
Emergence of the long form of hepatitis delta virus antigen in transfected cells after intrahepatic transfection and during natural infection. (1993) (4)
Molecular pathophysiology of persistent hepatitis B virus infection in relation to chronic liver disease and primary hepatocellular carcinoma. (1987) (3)
Measurement of hepatitis B viral DNA in serum by solution hybridization and comparison with the dot-blot hybridization technique. (1991) (3)
Australia antigen (HBsAg) carriers in a Greek community. Studies of transaminase (SGPT) levels. (1975) (3)
Significance of HBV viremia levels estimated by a quantitative PCR assay in the evaluation of HBeAg negative chronic HBV infection (2001) (3)
Efficacy of long term lamivudine therapy in HBeAg negative chronic hepatitis B (2000) (3)
O.047 Treatment paradigms in hepatitis B e antigen negative (HBeAg-negative) chronic hepatitis B patients (2006) (3)
Treatment options for chronic hepatitis B not responding to interferon. (2003) (3)
421 A new bio-mathematical model to describe the dynamics of HBV-DNA and infected hepatocytes in HBEAG-negative/anti-HBE-positive chronic hepatitis B patients treated with peginterferon alfa-2A (40KD) (PEGASYS®), lamivudine, or PEGASYS® plus lamivudine combin (2004) (3)
CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years (2006) (3)
Hepatitis B vaccination strategy for health-care workers in a country of intermediate hepatitis B endemicity. (1983) (3)
Glucose intolerance in chronic hepatitis C and B: risk factors and prevalence in general population (2002) (3)
Primary liver cancer and its relationship to chronic infection with the hepatitis B virus (1981) (2)
Quantitative HBsAg titer as predictor of response to therapy (2009) (2)
436 Models to predict inflammation and fibrosis in patients with chronic hepatitis B (2004) (2)
Point mutations in the pre-core region of HBV in anti-HBe positive patients with chronic hepatitis and persistent HBV replication (1989) (2)
1156 48 weeks of adefovir dipivoxil (ADV) results in a consistent and significant improvement in liver histology and virological status regardless of baseline knodell fibrosis score in patients with HBEAG- chronic hepatitis B (2003) (2)
828 TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN OLDER HCV GENOTYPE 1 PATIENTS WITH POSITIVE PROGNOSTIC FACTORS LEADS TO HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE (2008) (2)
Prognostic factors determining the outcome of treatment in chronic hepatitis C. (2000) (2)
Hepatitis G virus or hepatitis GB virus type C infection in thalassemic patients (1999) (2)
442 Entecavir 10 mg is consistently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine-refractory patients (2004) (2)
Course of virologic breakthroughs under lamivudine therapy in patients with precore mutant HBV related liver disease (2001) (2)
Combination of interferon alpha therapy with non-steroidal anti-inflammatory drugs in chronic hepatitis C. (2000) (2)
Hepatocellular carcinoma (HCC) and extrahepatic malignancies in primary biliary cirrhosis (PBC) (2001) (2)
Letter: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients (2016) (2)
Effects of Alcohol on Hepatic Mitochondrial Function and DNA (1999) (2)
Thrombotic risk factors and extent of liver fibrosis in patients with chronic viral hepatitis (CH) (2002) (2)
Clinical expression of HDV infection: presentation of illustrative cases. (1993) (1)
Serum HBV-DNA in delta antigen positive chronic liver disease. (1985) (1)
Danazol induced acute icteric cholestatic hepatitis (2007) (1)
Modern trends in the management of hepatocellular carcinoma. (1986) (1)
Use of a-interferon in the treatment of chronic dalte hepatitis (1991) (1)
M1910 Tenofovir Disoproxil Fumarate (TDF) Is Highly Active for Treatment of Chronic Hepatitis B in Subjects with Cirrhosis (2008) (1)
[487] PREDICTORS OF HBsAg REDUCTION IN HBsAg- NEGATIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) ALONE OR IN COMBINATION WITH LAMIVUDINE (2007) (1)
Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg‐negative chronic hepatitis B (2012) (1)
DISTRIBUTION OF IN VITRO EXPRESSED HBV CORE PROTEIN FROM ISOLATES IS DEPENDENT UPON SEQUENCE AND CORRELATES WITH DISEASE PATTERN (2004) (1)
Commentary: efficacy and safety of ribavirin plus pegylated interferon‐alpha in geriatric patients with chronic hepatitis C (2013) (1)
491 Peginterferon alpha-2a (40KD) (PEGASYS) reverses cirrhosis, improves fibrosis and slows progression of fibrosis in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B (CHB) (2006) (1)
PREDICTORS OF PREMATURE WITHDRAWAL AND DOSE REDUCTIONS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) PLUS RIBAVIRIN IN A LARGE, MULTINATIONAL, OPEN-LABEL EXPANDED ACCESS PROGRAM (2009) (1)
1063 Quantitative analysis of hepatitis B virus replicative intermediates in the liver: a comparison of pregenomic RNA vs cccDNA comparison of pregenomic RNA vs cccDNA detection (2003) (1)
Pre‐S1 and pre‐S2 gene‐encoded proteins in liver and serum in chronic hepatitis delta infection (1991) (1)
Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection? (2014) (1)
Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B (2022) (1)
Delta antigen positive chronic liver disease in Greece: clinical aspects and natural course. (1983) (1)
What Should Be the Endpoints of Oral Therapy in HBeAg-positive Versus HBeAg-negative Patients with Chronic Hepatitis B (2012) (1)
Randomised trial in HBeAg negative chronic hepatitis B of oral nucleoside analogues in combination with interferon (1998) (1)
1159 Lack of ethnic differences in response to adefovir dipivoxil therapy in HBEAG+ and HBEAG- patients with chronic hepatitis B (2003) (1)
Chronic viral hepatitis. (1974) (1)
Letter: safe and effective cessation of long‐term nucleos(t)ide analogue therapy in noncirrhotic patients with HBeAg‐negative chronic hepatitis B (2015) (1)
High incidenceof HBV pred-core gene translation initiation mutations in e antigen-negative patients (1995) (1)
494 Two-state modeling of virological and biochemical efficacy plus liver biopsies demonstrate efficacy of adefovir dipivoxil in HBeAg-negative chronic hepatitis B over four or five years (2006) (1)
Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen. (2016) (1)
Current treatment options for HBV infection (2009) (1)
Mutation of HBcAg after loss of HBeAg and association with progressive disease (1992) (1)
Pre-S2 and its antibody in fulminant type B hepatitis. (1989) (1)
Clinical Features of Hepatitis Delta Virus (2006) (1)
Controlling hepatitis C (2001) (1)
PF-03491390 INHIBITS LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION VIA SUPPRESSION OF PRO-APOPTOTIC CASPASE-ACTIVA- TION. (2007) (1)
Long-term interferon therapy and low levels of HCV viraemia in chronic hepatitis C are associated with high rates of sustained response (1994) (0)
Interferon therapy for prevention of hepatocellular cancer in patients with HCV related cirrhosis: A meta-analysis (2000) (0)
Limitations of retrospective IL28B polymorphisms and IP‐10 real life studies in hepatitis C (2011) (0)
Contents Vol. 20, 2002 (2002) (0)
Effectiveness of interferon alfa in caucasian patients with viral compensated cirrhosis (1997) (0)
Diabetes mellitus (DM) and staging of chronic viral hepatitis (CH) (2002) (0)
[658] OPTIMAL PRE-TREATMENT HCV-RNA LEVEL FOR PREDICTION OF SVR WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN IN GENOTYPE 1 PATIENTS: GENERALISED ADDITIVE LOGISTIC REGRESSION MODEL (GAM) ANALYSIS (2007) (0)
Effect of antiviral therapy on the immunohistochemical expression of bcl‐xL and bax protein in patients with HBeAg‐negative chronic hepatitis B (2011) (0)
Clinical course after liver transplantation in patients infected with the precore 1896a HBV mutant (2001) (0)
The relative roles of HBV and HCV in the etiology of HCC in Greece. Epidemiological and clinical characteristics (2001) (0)
Erratum to: “Natural history of chronic hepatitis B in Euro-Mediterranean and African Countries” [J Hepatol 2011;55:183–191] (2013) (0)
Use of a monoclonal antibody in the detection of HBsAg in the liver by immunofluorescence. (1983) (0)
Size of the speciality. (1989) (0)
P.112 Response is sustained two years post-treatment in the majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] (2006) (0)
[480] LONGITUDINAL CHANGES IN SERUM HBV-DNA LEVELS DURING THE NATURAL COURSE OF HBeAg-NEGATIVE CHRONIC HEPATITIS B VIRUS (HBV) INFECTION (2007) (0)
HCV-RNA levels by branched DNA signal amplification as a predictor of sustained response to alpha interferon treatment (1993) (0)
O.183 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026) (2006) (0)
Efficacy of 3 vs. 5 MU IFN-alpha given daily followed by a tiw maintenance regimen in chronic hepatitis C: a randomized trial (1998) (0)
P.105 Final analysis of virological outcomes and resistance during 5 years of adefovir dipivoxil monotherapy in hepatitis B e antigen-negative patients (2006) (0)
Hepatocellular carcinoma (HCC) in cirrhosis type B: risk factors in 366 western european patients (1993) (0)
Subject Index Vol. 20, 2002 (2003) (0)
Analysis of HBV DNA Molecules, Viral Antigens and Antibodies, Virus Replication and Liver Disease Activity in Patients with Persistent Hepatitis B Virus Infection (1983) (0)
A critical appraisal of current approaches to treatment of chronic hepatitis B (CHB)based on a review by an international panel of investigators and a survey of AASLD membership (2005) (0)
Clinical course of compensated cirrhosis type B: a European multicenter study (1992) (0)
Research as a part of education. (1989) (0)
Liver and biliary Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection (2006) (0)
Title Predicting response to peginterferon α2 a , lamivudine and thetwo combined for HBeAg-negative chronic hepatitis B (2007) (0)
Contribution oflowlevel HBV replication tocontinuing inflammatory activity inpatients withanti-HBe positive chronic hepatitis Bvirus infection (1984) (0)
Hepatitis delta virus : molecular biology, pathogenesis, and clinical aspects : proceedings of the Fourth International Symposium on Heptitis Delta Virus, held at Rhodes, Greece, June 8-10, 1992 (1993) (0)
Long-term lamivudine monotherapy (LAM) in patients with HBeAg-negative HBV related chronic liver disease [HBeAg(−)CLD]: predictors of virological (VBTs) and biochemical (BBTs) breakthroughs (2002) (0)
Persistent HBV infection in HBeAg negative active liver disease is associated with aminoacid substitutions in B and T-helper cell epitopes rather than in CTL epitopes (1994) (0)
Characteristics and outcome of biochemical breakthroughs (BBTS) in patients with HBeAg-negative HBV related chronic liver disease [HBeAg(-)CLD] under long-term lamivudine monotherapy (LAM) (2002) (0)
PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) HAS A WIDE SAFETY MARGIN IN COMBINATION WITH RIBAVIRIN (RBV) 1000/1200 MG/DAY IN PATIENTS INFECTED WITH HCV GENOTYPE 1: POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED MULTICENTER STUDIES (2009) (0)
Course of virologic breakthroughs (VBTs) under lamivudine (LAM) therapy in patients (PTS) with precore mutant HBV related chronic liver disease (CLD) (2001) (0)
[Activity of the monooxygenase enzyme system in the liver of "healthy" HBsAg carriers]. (1985) (0)
Hepatocellular carcinoma in western european patients with compensated cirrhosis type B: a multicenter study (1993) (0)
Serum HBsAg loss in compensated cirrhosis B: relation to interferon alpha therapy and liver disease prognosis (1998) (0)
Original contributionSignificance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen–negative chronic hepatitis B virus infection (2003) (0)
Diagnostic value of anti-alpha FP antibody levels in a metastatic germ cell tumor of unknown primary site. (1999) (0)
34 Anti-HBc positivity and gender are strongly related to HCC but are not related to treatment outcome (2004) (0)
Combination of interferon α therapy with non-steroidal anti-inflammatory drugs in chronic hepatitis C (2000) (0)
Core protein substitution, anti-HBe positive chronic hepatitis and B cell epitopes (1995) (0)
682 HBVDNA SUPPRESSION INDUCED BY PEGINTERFERON ALFA-2A (40KD) BUT NOT BY LAMIVUDINE RESULTS IN HBSAG LOSS AND SEROCONVERSION AT 3 YEARS POST-TREATMENT (2008) (0)
T1990 Peginterferon Alfa-2a (40KD) Has a Wide Safety Margin in Patients Infected With Hepatitis C Virus Genotype 1: Pooled Data From Four Randomized Multicenter Studies (2010) (0)
519 Long-term occurrence of liver complications in hepatitis C patients. Association with host and viral factors (2004) (0)
Quantitative detection and replicative activity of hepatitis B virus CCCDNA in the liver in chronic HBV infection (2003) (0)
Commentary: combination therapy with two nucleos(t)ide analogues in chronic hepatitis B (2012) (0)
532 THROMBIN GENERATION IN PATIENTS WITH LIVER CIRRHOSIS (2010) (0)
Spontaneous bacterial peritonitis (SBP): clinical, laboratory and prognostic features. A single center experience (2001) (0)
Viral and host factors contribute to fulminant hepatitis following infection with the hbeag negative variant (1998) (0)
Application of an enzymatic fluorimetric method in the quantitation of serum ursodeoxycholic acid in primary biliary cirrhosis under ursodeoxycholic therapy (1992) (0)
Long-term outcome of chronic hepatitis C treated with interferon. (1999) (0)
Serum hepatitis B virus RNA detectability, composition and clinical significance in patients with ab initio hepatitis B e antigen negative chronic hepatitis B (2022) (0)
with repeat determinations of serum aminotransferase levels followed by repeat HBV DNA testing if aminotransferase values rise. (2002) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stephanos J. Hadziyannis?

Stephanos J. Hadziyannis is affiliated with the following schools:

National and Kapodistrian University of Athens

Stephanos J. Hadziyannis's Academic­Influence.com Rankings

Why Is Stephanos J. Hadziyannis Influential?

Stephanos J. Hadziyannis's Published Works

Published Works

What Schools Are Affiliated With Stephanos J. Hadziyannis?

Stephanos J. Hadziyannis's AcademicInfluence.com Rankings